{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:38:41Z","timestamp":1794134321143,"version":"4.8.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41569-018-0108-7","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T06:21:47Z","timestamp":1541658107000},"page":"137-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":739,"title":["Dietary metabolism, the gut microbiome, and heart failure"],"prefix":"10.1038","volume":"16","author":[{"given":"W. H. Wilson","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Hazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"108_CR1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy, C. W. et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 128, 1810\u20131852 (2013).","journal-title":"Circulation"},{"key":"108_CR2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy, C. W. et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 70, 776\u2013803 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0002-9149(97)00159-8","volume":"79","author":"SD Anker","year":"1997","unstructured":"Anker, S. D. et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am. J. Cardiol. 79, 1426\u20131430 (1997).","journal-title":"Am. J. Cardiol."},{"key":"108_CR4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehi389","volume":"26","author":"A Krack","year":"2005","unstructured":"Krack, A., Sharma, R., Figulla, H. R. & Anker, S. D. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur. Heart J. 26, 2368\u20132374 (2005).","journal-title":"Eur. Heart J."},{"key":"108_CR5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLOS Biol. 14, e1002533 (2016).","journal-title":"PLOS Biol."},{"key":"108_CR6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","volume":"449","author":"PJ Turnbaugh","year":"2007","unstructured":"Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804\u2013810 (2007).","journal-title":"Nature"},{"key":"108_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.tree.2006.06.013","volume":"21","author":"L Dethlefsen","year":"2006","unstructured":"Dethlefsen, L., Eckburg, P. B., Bik, E. M. & Relman, D. A. Assembly of the human intestinal microbiota. Trends Ecol. Evol. 21, 517\u2013523 (2006).","journal-title":"Trends Ecol. Evol."},{"key":"108_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature11234","volume":"486","author":"Human Microbiome Project Consortium","year":"2012","unstructured":"Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207\u2013214 (2012).","journal-title":"Nature"},{"key":"108_CR9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/17460913.2.3.285","volume":"2","author":"CC Booijink","year":"2007","unstructured":"Booijink, C. C., Zoetendal, E. G., Kleerebezem, M. & de Vos, W. M. Microbial communities in the human small intestine: coupling diversity to metagenomics. Future Microbiol. 2, 285\u2013295 (2007).","journal-title":"Future Microbiol."},{"key":"108_CR10","unstructured":"Gorbach, S. L. in Medical Microbiology 4th edn (ed. Baron, S.) (Univ. of Texas Medical Branch, 1996)."},{"key":"108_CR11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1126\/science.291.5505.881","volume":"291","author":"LV Hooper","year":"2001","unstructured":"Hooper, L. V. et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291, 881\u2013884 (2001).","journal-title":"Science"},{"key":"108_CR12","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1021\/jf9044205","volume":"58","author":"A Marcobal","year":"2010","unstructured":"Marcobal, A. et al. Consumption of human milk oligosaccharides by gut-related microbes. J. Agr. Food Chem. 58, 5334\u20135340 (2010).","journal-title":"J. Agr. Food Chem."},{"key":"108_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121\u2013141 (2014).","journal-title":"Cell"},{"key":"108_CR14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chom.2007.05.004","volume":"1","author":"M Fujiya","year":"2007","unstructured":"Fujiya, M. et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 1, 299\u2013308 (2007).","journal-title":"Cell Host Microbe"},{"key":"108_CR15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri3535","volume":"13","author":"CG Buffie","year":"2013","unstructured":"Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790\u2013801 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"108_CR16","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1073\/pnas.0700440104","volume":"104","author":"SC Corr","year":"2007","unstructured":"Corr, S. C. et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl Acad. Sci. USA 104, 7617\u20137621 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/j.1462-2920.2007.01369.x","volume":"9","author":"M Rajilic-Stojanovic","year":"2007","unstructured":"Rajilic-Stojanovic, M., Smidt, H. & de Vos, W. M. Diversity of the human gastrointestinal tract microbiota revisited. Environ. Microbiol. 9, 2125\u20132136 (2007).","journal-title":"Environ. Microbiol."},{"key":"108_CR18","volume":"4","author":"X Yang","year":"2009","unstructured":"Yang, X., Xie, L., Li, Y. & Wei, C. More than 9,000,000 unique genes in human gut bacterial community: estimating gene numbers inside a human body. PLOS ONE 4, e6074 (2009).","journal-title":"PLOS ONE"},{"key":"108_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050177","volume":"5","author":"C Palmer","year":"2007","unstructured":"Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A. & Brown, P. O. Development of the human infant intestinal microbiota. PLOS Biol. 5, e177 (2007).","journal-title":"PLOS Biol."},{"key":"108_CR20","doi-asserted-by":"crossref","first-page":"11971","DOI":"10.1073\/pnas.1002601107","volume":"107","author":"MG Dominguez-Bello","year":"2010","unstructured":"Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107, 11971\u201311975 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nm.4272","volume":"23","author":"DM Chu","year":"2017","unstructured":"Chu, D. M. et al. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery. Nat. Med. 23, 314\u2013326 (2017).","journal-title":"Nat. Med."},{"key":"108_CR22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrg.2017.63","volume":"18","author":"AB Hall","year":"2017","unstructured":"Hall, A. B., Tolonen, A. C. & Xavier, R. J. Human genetic variation and the gut microbiome in disease. Nat. Rev. Genet. 18, 690\u2013699 (2017).","journal-title":"Nat. Rev. Genet."},{"key":"108_CR23","doi-asserted-by":"crossref","DOI":"10.1126\/science.aag2770","volume":"356","author":"N Koppel","year":"2017","unstructured":"Koppel, N., Maini Rekdal, V. & Balskus, E. P. Chemical transformation of xenobiotics by the human gut microbiota. Science 356, eaag2770 (2017).","journal-title":"Science"},{"key":"108_CR24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature18846","volume":"535","author":"JL Sonnenburg","year":"2016","unstructured":"Sonnenburg, J. L. & Backhed, F. Diet-microbiota interactions as moderators of human metabolism. Nature 535, 56\u201364 (2016).","journal-title":"Nature"},{"key":"108_CR25","doi-asserted-by":"crossref","first-page":"8560","DOI":"10.1074\/jbc.R116.765388","volume":"292","author":"JM Brown","year":"2017","unstructured":"Brown, J. M. & Hazen, S. L. Targeting of microbe-derived metabolites to improve human health: the next frontier for drug discovery. J. Biol. Chem. 292, 8560\u20138568 (2017).","journal-title":"J. Biol. Chem."},{"key":"108_CR26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/00498254.2013.811314","volume":"44","author":"KS Saitta","year":"2014","unstructured":"Saitta, K. S. et al. Bacterial beta-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 44, 28\u201335 (2014).","journal-title":"Xenobiotica"},{"key":"108_CR27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.chembiol.2015.08.005","volume":"22","author":"BD Wallace","year":"2015","unstructured":"Wallace, B. D. et al. Structure and inhibition of microbiome \u03b2-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22, 1238\u20131249 (2015).","journal-title":"Chem. Biol."},{"key":"108_CR28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1126\/science.270.5239.1203","volume":"270","author":"ML Hermiston","year":"1995","unstructured":"Hermiston, M. L. & Gordon, J. I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270, 1203\u20131207 (1995).","journal-title":"Science"},{"key":"108_CR29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2007.07.016","volume":"50","author":"A Sandek","year":"2007","unstructured":"Sandek, A. et al. Altered intestinal function in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1561\u20131569 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR30","first-page":"154","volume":"110","author":"MP Fink","year":"1991","unstructured":"Fink, M. P., Kaups, K. L., Wang, H. L. & Rothschild, H. R. Maintenance of superior mesenteric arterial perfusion prevents increased intestinal mucosal permeability in endotoxic pigs. Surgery 110, 154\u2013160 (1991).","journal-title":"Surgery"},{"key":"108_CR31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis, F. et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54, 1747\u20131762 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0016-5085(86)90463-4","volume":"91","author":"M Jodal","year":"1986","unstructured":"Jodal, M. & Lundgren, O. Countercurrent mechanisms in the mammalian gastrointestinal tract. Gastroenterology 91, 225\u2013241 (1986).","journal-title":"Gastroenterology"},{"key":"108_CR33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jama.1993.03510100053032","volume":"270","author":"N Maynard","year":"1993","unstructured":"Maynard, N. et al. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA 270, 1203\u20131210 (1993).","journal-title":"JAMA"},{"key":"108_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejheart.2004.03.002","volume":"6","author":"A Krack","year":"2004","unstructured":"Krack, A. et al. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur. J. Heart Fail. 6, 403\u2013407 (2004).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijcard.2007.11.103","volume":"125","author":"GP Arutyunov","year":"2008","unstructured":"Arutyunov, G. P., Kostyukevich, O. I., Serov, R. A., Rylova, N. V. & Bylova, N. A. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int. J. Cardiol. 125, 240\u2013245 (2008).","journal-title":"Int. J. Cardiol."},{"key":"108_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cyto.2008.01.006","volume":"42","author":"YC Lu","year":"2008","unstructured":"Lu, Y. C., Yeh, W. C. & Ohashi, P. S. LPS\/TLR4 signal transduction pathway. Cytokine 42, 145\u2013151 (2008).","journal-title":"Cytokine"},{"key":"108_CR37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis, N. G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 11, 255\u2013265 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"108_CR38","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/S0140-6736(98)09286-1","volume":"353","author":"J Niebauer","year":"1999","unstructured":"Niebauer, J. et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353, 1838\u20131842 (1999).","journal-title":"Lancet"},{"key":"108_CR39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1388-9842(03)00104-1","volume":"5","author":"T Peschel","year":"2003","unstructured":"Peschel, T. et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur. J. Heart Fail. 5, 609\u2013614 (2003).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/SHK.0b013e3181a2bcd6","volume":"32","author":"F Hietbrink","year":"2009","unstructured":"Hietbrink, F. et al. Systemic inflammation increases intestinal permeability during experimental human endotoxemia. Shock 32, 374\u2013378 (2009).","journal-title":"Shock"},{"key":"108_CR41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9149(97)89206-5","volume":"77","author":"MA Munger","year":"1996","unstructured":"Munger, M. A., Johnson, B., Amber, I. J., Callahan, K. S. & Gilbert, E. M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 77, 723\u2013727 (1996).","journal-title":"Am. J. Cardiol."},{"key":"108_CR42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1388-9842(99)00049-5","volume":"1","author":"WJ Paulus","year":"1999","unstructured":"Paulus, W. J. How are cytokines activated in heart failure? Eur. J. Heart Fail. 1, 309\u2013312 (1999).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR43","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","volume":"103","author":"A Deswal","year":"2001","unstructured":"Deswal, A. et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103, 2055\u20132059 (2001).","journal-title":"Circulation"},{"key":"108_CR44","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","volume":"102","author":"M Rauchhaus","year":"2000","unstructured":"Rauchhaus, M. et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102, 3060\u20133067 (2000).","journal-title":"Circulation"},{"key":"108_CR45","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/01.CIR.92.6.1479","volume":"92","author":"R Ferrari","year":"1995","unstructured":"Ferrari, R. et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92, 1479\u20131486 (1995).","journal-title":"Circulation"},{"key":"108_CR46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejheart.2003.12.004","volume":"6","author":"VM Conraads","year":"2004","unstructured":"Conraads, V. M. et al. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur. J. Heart Fail. 6, 483\u2013491 (2004).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR47","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","volume":"116","author":"DL Mann","year":"2015","unstructured":"Mann, D. L. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ. Res. 116, 1254\u20131268 (2015).","journal-title":"Circ. Res."},{"key":"108_CR48","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.97.14.1382","volume":"97","author":"B Bozkurt","year":"1998","unstructured":"Bozkurt, B. et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97, 1382\u20131391 (1998).","journal-title":"Circulation"},{"key":"108_CR49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.RES.81.4.627","volume":"81","author":"T Kubota","year":"1997","unstructured":"Kubota, T. et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81, 627\u2013635 (1997).","journal-title":"Circ. Res."},{"key":"108_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085345","volume":"9","author":"R Al-Sadi","year":"2014","unstructured":"Al-Sadi, R. et al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLOS ONE 9, e85345 (2014).","journal-title":"PLOS ONE"},{"key":"108_CR51","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.4049\/jimmunol.178.7.4641","volume":"178","author":"RM Al-Sadi","year":"2007","unstructured":"Al-Sadi, R. M. & Ma, T. Y. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J. Immunol. 178, 4641\u20134649 (2007).","journal-title":"J. Immunol."},{"key":"108_CR52","doi-asserted-by":"crossref","first-page":"G422","DOI":"10.1152\/ajpgi.00412.2004","volume":"288","author":"TY Ma","year":"2005","unstructured":"Ma, T. Y., Boivin, M. A., Ye, D., Pedram, A. & Said, H. M. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G422\u2013G430 (2005).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"108_CR53","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ajpath.2013.09.001","volume":"183","author":"R Al-Sadi","year":"2013","unstructured":"Al-Sadi, R., Guo, S., Ye, D. & Ma, T. Y. TNF-alpha modulation of intestinal epithelial tight junction barrier is regulated by ERK1\/2 activation of Elk-1. Am. J. Pathol. 183, 1871\u20131884 (2013).","journal-title":"Am. J. Pathol."},{"key":"108_CR54","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133\u20133140 (2003).","journal-title":"Circulation"},{"key":"108_CR55","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594\u20131602 (2004).","journal-title":"Circulation"},{"key":"108_CR56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(08)60134-8","volume":"371","author":"G Torre-Amione","year":"2008","unstructured":"Torre-Amione, G. et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 371, 228\u2013236 (2008).","journal-title":"Lancet"},{"key":"108_CR57","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"108_CR58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/eurjhf\/hfq017","volume":"12","author":"A Abbate","year":"2010","unstructured":"Abbate, A. et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur. J. Heart Fail. 12, 319\u2013322 (2010).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR59","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","volume":"117","author":"A Abbate","year":"2008","unstructured":"Abbate, A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670\u20132683 (2008).","journal-title":"Circulation"},{"key":"108_CR60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/FJC.0b013e3181c87e53","volume":"55","author":"BW Tassell Van","year":"2010","unstructured":"Van Tassell, B. W. et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J. Cardiovasc. Pharmacol. 55, 117\u2013122 (2010).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"108_CR61","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","volume":"10","author":"BW Tassell Van","year":"2017","unstructured":"Van Tassell, B. W. et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ. Heart Fail. 10, e004373 (2017).","journal-title":"Circ. Heart Fail"},{"key":"108_CR62","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/clc.22719","volume":"40","author":"BW Tassell Van","year":"2017","unstructured":"Van Tassell, B. W. et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin. Cardiol. 40, 626\u2013632 (2017).","journal-title":"Clin. Cardiol."},{"key":"108_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01900600 (2017)."},{"key":"108_CR64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000338166","volume":"122","author":"L Gullestad","year":"2012","unstructured":"Gullestad, L. et al. Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122, 23\u201335 (2012).","journal-title":"Cardiology"},{"key":"108_CR65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick, S. A. & Epelman, S. Chronic heart failure and inflammation: what do we really know? Circ. Res. 119, 159\u2013176 (2016).","journal-title":"Circ. Res."},{"key":"108_CR66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.15252\/embr.201439263","volume":"16","author":"HE Jakobsson","year":"2015","unstructured":"Jakobsson, H. E. et al. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 16, 164\u2013177 (2015).","journal-title":"EMBO Rep."},{"key":"108_CR67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/cmi.2010.67","volume":"8","author":"H Tlaskalova-Hogenova","year":"2011","unstructured":"Tlaskalova-Hogenova, H. et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell. Mol. Immunol. 8, 110\u2013120 (2011).","journal-title":"Cell. Mol. Immunol."},{"key":"108_CR68","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/4441022a","volume":"444","author":"RE Ley","year":"2006","unstructured":"Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022\u20131023 (2006).","journal-title":"Nature"},{"key":"108_CR69","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027\u20131031 (2006).","journal-title":"Nature"},{"key":"108_CR70","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2012-13-9-r79","volume":"13","author":"XC Morgan","year":"2012","unstructured":"Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012).","journal-title":"Genome Biol."},{"key":"108_CR71","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature07336","volume":"455","author":"L Wen","year":"2008","unstructured":"Wen, L. et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455, 1109\u20131113 (2008).","journal-title":"Nature"},{"key":"108_CR72","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55\u201360 (2012).","journal-title":"Nature"},{"key":"108_CR73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"Kummen, M. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66, 611\u2013619 (2017).","journal-title":"Gut"},{"key":"108_CR74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.chom.2014.02.007","volume":"15","author":"CL Sears","year":"2014","unstructured":"Sears, C. L. & Garrett, W. S. Microbes, microbiota, and colon cancer. Cell Host Microbe 15, 317\u2013328 (2014).","journal-title":"Cell Host Microbe"},{"key":"108_CR75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1224820","volume":"338","author":"JC Arthur","year":"2012","unstructured":"Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120\u2013123 (2012).","journal-title":"Science"},{"key":"108_CR76","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","volume":"62","author":"T Roy Le","year":"2013","unstructured":"Le Roy, T. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787\u20131794 (2013).","journal-title":"Gut"},{"key":"108_CR77","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1073\/pnas.0601056103","volume":"103","author":"ME Dumas","year":"2006","unstructured":"Dumas, M. E. et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA 103, 12511\u201312516 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR78","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.cell.2013.11.024","volume":"155","author":"EY Hsiao","year":"2013","unstructured":"Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451\u20131463 (2013).","journal-title":"Cell"},{"key":"108_CR79","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tins.2013.01.005","volume":"36","author":"JA Foster","year":"2013","unstructured":"Foster, J. A. & McVey Neufeld, K. A. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 36, 305\u2013312 (2013).","journal-title":"Trends Neurosci."},{"key":"108_CR80","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/nmo.12378","volume":"26","author":"A Naseribafrouei","year":"2014","unstructured":"Naseribafrouei, A. et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol. Motil. 26, 1155\u20131162 (2014).","journal-title":"Neurogastroenterol Motil."},{"key":"108_CR81","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1074\/jbc.M114.618249","volume":"290","author":"JC Gregory","year":"2015","unstructured":"Gregory, J. C. et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 290, 5647\u20135660 (2015).","journal-title":"J. Biol. Chem."},{"key":"108_CR82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","volume":"165","author":"W Zhu","year":"2016","unstructured":"Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111\u2013124 (2016).","journal-title":"Cell"},{"key":"108_CR83","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1073\/pnas.1215927110","volume":"110","author":"JL Pluznick","year":"2013","unstructured":"Pluznick, J. L. et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl Acad. Sci. USA 110, 4410\u20134415 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1152\/physiolgenomics.00136.2014","volume":"47","author":"B Mell","year":"2015","unstructured":"Mell, B. et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol. Genom. 47, 187\u2013197 (2015).","journal-title":"Physiol. Genom."},{"key":"108_CR85","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.115.06672","volume":"67","author":"DJ Durgan","year":"2016","unstructured":"Durgan, D. J. et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67, 469\u2013474 (2016).","journal-title":"Hypertension"},{"key":"108_CR86","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1096\/fj.11-197921","volume":"26","author":"V Lam","year":"2012","unstructured":"Lam, V. et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 26, 1727\u20131735 (2012).","journal-title":"FASEB J."},{"key":"108_CR87","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.06.1179","volume":"64","author":"A Sandek","year":"2014","unstructured":"Sandek, A. et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J. Am. Coll. Cardiol. 64, 1092\u20131102 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR88","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jchf.2015.10.009","volume":"4","author":"E Pasini","year":"2016","unstructured":"Pasini, E. et al. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail. 4, 220\u2013227 (2016).","journal-title":"JACC Heart Fail"},{"key":"108_CR89","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cardfail.2016.06.005","volume":"22","author":"P Mamic","year":"2016","unstructured":"Mamic, P., Heidenreich, P. A., Hedlin, H., Tennakoon, L. & Staudenmayer, K. L. Hospitalized patients with heart failure and common bacterial infections: a nationwide analysis of concomitant Clostridium difficile infection rates and in-hospital mortality. J. Card. Fail. 22, 891\u2013900 (2016).","journal-title":"J. Card Fail"},{"key":"108_CR90","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ehf2.12155","volume":"4","author":"M Luedde","year":"2017","unstructured":"Luedde, M. et al. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail. 4, 282\u2013290 (2017).","journal-title":"ESC Heart Fail"},{"key":"108_CR91","volume":"8","author":"X Cui","year":"2018","unstructured":"Cui, X. et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci. Rep. 8, 635 (2018).","journal-title":"Sci. Rep."},{"key":"108_CR92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174099","volume":"12","author":"T Kamo","year":"2017","unstructured":"Kamo, T. et al. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLOS ONE 12, e0174099 (2017).","journal-title":"PLOS ONE"},{"key":"108_CR93","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jacc.2017.12.057","volume":"71","author":"M Kummen","year":"2018","unstructured":"Kummen, M. et al. Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts. J. Am. Coll. Cardiol. 71, 1184\u20131186 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR94","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fmicb.2016.00713","volume":"7","author":"C Engels","year":"2016","unstructured":"Engels, C., Ruscheweyh, H. J., Beerenwinkel, N., Lacroix, C. & Schwab, C. The common gut microbe Eubacterium hallii also contributes to intestinal propionate formation. Front. Microbiol. 7, 713 (2016).","journal-title":"Front. Microbiol."},{"key":"108_CR95","volume":"3","author":"FH Karlsson","year":"2012","unstructured":"Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 3, 1245 (2012).","journal-title":"Nat. Commun."},{"key":"108_CR96","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.cell.2015.11.055","volume":"163","author":"Z Wang","year":"2015","unstructured":"Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585\u20131595 (2015).","journal-title":"Cell"},{"key":"108_CR97","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nature25973","volume":"555","author":"D Rothschild","year":"2018","unstructured":"Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210\u2013215 (2018).","journal-title":"Nature"},{"key":"108_CR98","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"},{"key":"108_CR99","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-017-0312-4","volume":"5","author":"JA Caparros-Martin","year":"2017","unstructured":"Caparros-Martin, J. A. et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5, 95 (2017).","journal-title":"Microbiome"},{"key":"108_CR100","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850\u2013858 (2017).","journal-title":"Nat. Med."},{"key":"108_CR101","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1126\/science.1235872","volume":"341","author":"HJ Haiser","year":"2013","unstructured":"Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295\u2013298 (2013).","journal-title":"Science"},{"key":"108_CR102","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565\u2013569 (2016).","journal-title":"Science"},{"key":"108_CR103","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1124\/dmd.115.063545","volume":"43","author":"FP Selwyn","year":"2015","unstructured":"Selwyn, F. P., Cui, J. Y. & Klaassen, C. D. RNA-seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab. Dispos. 43, 1572\u20131580 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"108_CR104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006958","volume":"4","author":"B Bjorkholm","year":"2009","unstructured":"Bjorkholm, B. et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLOS ONE 4, e6958 (2009).","journal-title":"PLOS ONE"},{"key":"108_CR105","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00271-10","volume":"2","author":"SP Claus","year":"2011","unstructured":"Claus, S. P. et al. Colonization-induced host-gut microbial metabolic interaction. MBio 2, e00271 (2011).","journal-title":"MBio"},{"key":"108_CR106","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","volume":"14","author":"P Spanogiannopoulos","year":"2016","unstructured":"Spanogiannopoulos, P., Bess, E. N., Carmody, R. N. & Turnbaugh, P. J. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273\u2013287 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"108_CR107","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1152\/physrev.2001.81.3.1031","volume":"81","author":"DL Topping","year":"2001","unstructured":"Topping, D. L. & Clifton, P. M. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81, 1031\u20131064 (2001).","journal-title":"Physiol. Rev."},{"key":"108_CR108","doi-asserted-by":"crossref","first-page":"G775","DOI":"10.1152\/ajpgi.2000.279.4.G775","volume":"279","author":"C Hadjiagapiou","year":"2000","unstructured":"Hadjiagapiou, C., Schmidt, L., Dudeja, P. K., Layden, T. J. & Ramaswamy, K. Mechanism(s) of butyrate transport in Caco-2 cells: role of monocarboxylate transporter 1. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G775\u2013G780 (2000).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"108_CR109","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0016-5085(91)90008-9","volume":"101","author":"N Mascolo","year":"1991","unstructured":"Mascolo, N., Rajendran, V. M. & Binder, H. J. Mechanism of short-chain fatty acid uptake by apical membrane vesicles of rat distal colon. Gastroenterology 101, 331\u2013338 (1991).","journal-title":"Gastroenterology"},{"key":"108_CR110","doi-asserted-by":"crossref","first-page":"G1217","DOI":"10.1152\/ajpgi.00415.2004","volume":"288","author":"S Vidyasagar","year":"2005","unstructured":"Vidyasagar, S., Barmeyer, C., Geibel, J., Binder, H. J. & Rajendran, V. M. Role of short-chain fatty acids in colonic HCO(3) secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G1217\u2013G1226 (2005).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"108_CR111","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1194\/jlr.R036012","volume":"54","author":"G Besten den","year":"2013","unstructured":"den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325\u20132340 (2013).","journal-title":"J. Lipid Res."},{"key":"108_CR112","first-page":"58","volume":"14","author":"JH Sellin","year":"1999","unstructured":"Sellin, J. H. SCFAs: the enigma of weak electrolyte transport in the colon. News Physiol. Sci. 14, 58\u201364 (1999).","journal-title":"News Physiol. Sci."},{"key":"108_CR113","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/j.1462-2920.2009.01931.x","volume":"11","author":"SH Duncan","year":"2009","unstructured":"Duncan, S. H., Louis, P., Thomson, J. M. & Flint, H. J. The role of pH in determining the species composition of the human colonic microbiota. Environ. Microbiol. 11, 2112\u20132122 (2009).","journal-title":"Environ. Microbiol."},{"key":"108_CR114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2672.1991.tb04442.x","volume":"70","author":"CA Cherrington","year":"1991","unstructured":"Cherrington, C. A., Hinton, M., Pearson, G. R. & Chopra, I. Short-chain organic acids at ph 5.0 kill Escherichia coli and Salmonella spp. without causing membrane perturbation. J. Appl. Bacteriol. 70, 161\u2013165 (1991).","journal-title":"J. Appl. Bacteriol."},{"key":"108_CR115","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jms.181","volume":"36","author":"E Pouteau","year":"2001","unstructured":"Pouteau, E., Meirim, I., Metairon, S. & Fay, L. B. Acetate, propionate and butyrate in plasma: determination of the concentration and isotopic enrichment by gas chromatography\/mass spectrometry with positive chemical ionization. J. Mass Spectrom. 36, 798\u2013805 (2001).","journal-title":"J. Mass Spectrom."},{"key":"108_CR116","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1161\/HYPERTENSIONAHA.115.05315","volume":"65","author":"T Yang","year":"2015","unstructured":"Yang, T. et al. Gut dysbiosis is linked to hypertension. Hypertension 65, 1331\u20131340 (2015).","journal-title":"Hypertension"},{"key":"108_CR117","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4161\/gmic.27492","volume":"5","author":"J Pluznick","year":"2014","unstructured":"Pluznick, J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 5, 202\u2013207 (2014).","journal-title":"Gut Microbes"},{"key":"108_CR118","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.116.024545","volume":"135","author":"FZ Marques","year":"2017","unstructured":"Marques, F. Z. et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135, 964\u2013977 (2017).","journal-title":"Circulation"},{"key":"108_CR119","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1079\/PNS2003208","volume":"62","author":"E Pouteau","year":"2003","unstructured":"Pouteau, E., Nguyen, P., Ballevre, O. & Krempf, M. Production rates and metabolism of short-chain fatty acids in the colon and whole body using stable isotopes. Proc. Nutr. Soc. 62, 87\u201393 (2003).","journal-title":"Proc. Nutr. Soc."},{"key":"108_CR120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre, P., Cariou, B., Lien, F., Kuipers, F. & Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147\u2013191 (2009).","journal-title":"Physiol. Rev."},{"key":"108_CR121","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","volume":"50","author":"PA Dawson","year":"2009","unstructured":"Dawson, P. A., Lan, T. & Rao, A. Bile acid transporters. J. Lipid Res. 50, 2340\u20132357 (2009).","journal-title":"J. Lipid Res."},{"key":"108_CR122","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nchembio.1864","volume":"11","author":"AS Devlin","year":"2015","unstructured":"Devlin, A. S. & Fischbach, M. A. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat. Chem. Biol. 11, 685\u2013690 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"108_CR123","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","volume":"47","author":"JM Ridlon","year":"2006","unstructured":"Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241\u2013259 (2006).","journal-title":"J. Lipid Res."},{"key":"108_CR124","doi-asserted-by":"crossref","first-page":"G256","DOI":"10.1152\/ajpgi.00027.2007","volume":"293","author":"JP Hamilton","year":"2007","unstructured":"Hamilton, J. P. et al. Human cecal bile acids: concentration and spectrum. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G256\u2013G263 (2007).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"108_CR125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cardfail.2017.06.007","volume":"23","author":"CCK Mayerhofer","year":"2017","unstructured":"Mayerhofer, C. C. K. et al. Increased secondary\/primary bile acid ratio in chronic heart failure. J. Card. Fail. 23, 666\u2013671 (2017).","journal-title":"J. Card Fail"},{"key":"108_CR126","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF00177718","volume":"335","author":"O Binah","year":"1987","unstructured":"Binah, O., Rubinstein, I., Bomzon, A. & Better, O. S. Effects of bile acids on ventricular muscle contraction and electrophysiological properties: studies in rat papillary muscle and isolated ventricular myocytes. Naunyn Schmiedebergs Arch. Pharmacol. 335, 160\u2013165 (1987).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"108_CR127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1681.1978.tb00645.x","volume":"5","author":"P Joubert","year":"1978","unstructured":"Joubert, P. An in vivo investigation of the negative chronotropic effect of cholic acid in the rat. Clin. Exp. Pharmacol. Physiol. 5, 1\u20138 (1978).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"108_CR128","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0006-2952(00)00259-8","volume":"59","author":"H Gazawi","year":"2000","unstructured":"Gazawi, H. et al. The effects of bile acids on beta-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochem. Pharmacol. 59, 1623\u20131628 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"108_CR129","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol. Cell 3, 543\u2013553 (1999).","journal-title":"Mol. Cell"},{"key":"108_CR130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","volume":"81","author":"BM Forman","year":"1995","unstructured":"Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687\u2013693 (1995).","journal-title":"Cell"},{"key":"108_CR131","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","volume":"278","author":"Y Kawamata","year":"2003","unstructured":"Kawamata, Y. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435\u20139440 (2003).","journal-title":"J. Biol. Chem."},{"key":"108_CR132","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","volume":"78","author":"H Rosen","year":"2009","unstructured":"Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G. & Brown, S. Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78, 743\u2013768 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"108_CR133","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000064347","volume":"65","author":"JP Raufman","year":"2002","unstructured":"Raufman, J. P., Chen, Y., Zimniak, P. & Cheng, K. Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology 65, 215\u2013221 (2002).","journal-title":"Pharmacology"},{"key":"108_CR134","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","volume":"13","author":"AC Calkin","year":"2012","unstructured":"Calkin, A. C. & Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 13, 213\u2013224 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"108_CR135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225\u2013235 (2013).","journal-title":"Cell Metab."},{"key":"108_CR136","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","volume":"48","author":"YD Wang","year":"2008","unstructured":"Wang, Y. D. et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48, 1632\u20131643 (2008).","journal-title":"Hepatology"},{"key":"108_CR137","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","volume":"27","author":"YT Li","year":"2007","unstructured":"Li, Y. T., Swales, K. E., Thomas, G. J., Warner, T. D. & Bishop-Bailey, D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 27, 2606\u20132611 (2007).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"108_CR138","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1073\/pnas.111155798","volume":"98","author":"NH Purcell","year":"2001","unstructured":"Purcell, N. H. et al. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl Acad. Sci. USA 98, 6668\u20136673 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR139","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.110.226928","volume":"108","author":"JW Gordon","year":"2011","unstructured":"Gordon, J. W., Shaw, J. A. & Kirshenbaum, L. A. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ. Res. 108, 1122\u20131132 (2011).","journal-title":"Circ. Res."},{"key":"108_CR140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/eurheartj\/ehs011","volume":"34","author":"J Pu","year":"2013","unstructured":"Pu, J. et al. Cardiomyocyte-expressed farnesoid-X-receptor is a novel apoptosis mediator and contributes to myocardial ischaemia\/reperfusion injury. Eur. Heart J. 34, 1834\u20131845 (2013).","journal-title":"Eur. Heart J"},{"key":"108_CR141","first-page":"5","volume":"3","author":"AH Ali","year":"2015","unstructured":"Ali, A. H., Carey, E. J. & Lindor, K. D. Recent advances in the development of farnesoid X receptor agonists. Ann. Transl Med. 3, 5 (2015).","journal-title":"Ann. Transl Med."},{"key":"108_CR142","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari, R. et al. 6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569\u20133572 (2002).","journal-title":"J. Med. Chem."},{"key":"108_CR143","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."},{"key":"108_CR144","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"108_CR145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574\u2013582 (2013).","journal-title":"Gastroenterology"},{"key":"108_CR146","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","volume":"64","author":"Y Xu","year":"2016","unstructured":"Xu, Y. et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64, 1072\u20131085 (2016).","journal-title":"Hepatology"},{"key":"108_CR147","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","volume":"51","author":"S Cipriani","year":"2010","unstructured":"Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats. J. Lipid Res. 51, 771\u2013784 (2010).","journal-title":"J. Lipid Res."},{"key":"108_CR148","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2011.10.880","volume":"59","author":"S Haehling von","year":"2012","unstructured":"von Haehling, S. et al. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J. Am. Coll. Cardiol. 59, 585\u2013592 (2012).","journal-title":"J. Am. Coll. Cardiol"},{"key":"108_CR149","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2362.1996.95240.x","volume":"26","author":"K Aouad","year":"1996","unstructured":"Aouad, K. et al. Immunosuppressive effects of endotoxins and bile acids in vivo in the rat. Eur. J. Clin. Invest. 26, 45\u201348 (1996).","journal-title":"Eur. J. Clin. Invest."},{"key":"108_CR150","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","volume":"19","author":"RA Koeth","year":"2013","unstructured":"Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576\u2013585 (2013).","journal-title":"Nat. Med"},{"key":"108_CR151","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","volume":"368","author":"WH Tang","year":"2013","unstructured":"Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575\u20131584 (2013).","journal-title":"N. Engl. J. Med."},{"key":"108_CR152","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57\u201363 (2011).","journal-title":"Nature"},{"key":"108_CR153","doi-asserted-by":"crossref","first-page":"1700299","DOI":"10.1002\/mnfr.201700299","volume":"62","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. The effect of different L-carnitine administration routes on the development of atherosclerosis in ApoE knockout mice. Mol. Nutr. Food Res. 62, 1700299 (2018).","journal-title":"Mol. Nutr. Food Res."},{"key":"108_CR154","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002314","volume":"9","author":"CL Organ","year":"2016","unstructured":"Organ, C. L. et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ. Heart Fail. 9, e002314 (2016).","journal-title":"Circ. Heart Fail"},{"key":"108_CR155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1242\/jeb.205.3.297","volume":"205","author":"BA Seibel","year":"2002","unstructured":"Seibel, B. A. & Walsh, P. J. Trimethylamine oxide accumulation in marine animals: relationship to acylglycerol storage. J. Exp. Biol. 205, 297\u2013306 (2002).","journal-title":"J. Exp. Biol."},{"key":"108_CR156","first-page":"307","volume":"53","author":"SN Parab","year":"1984","unstructured":"Parab, S. N. & Rao, S. B. Distribution of trimethylamine oxie in some marine and freshwater fish. Curr. Sci. 53, 307\u2013309 (1984).","journal-title":"Curr. Sci."},{"key":"108_CR157","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s11745-014-3932-5","volume":"49","author":"DP Cladis","year":"2014","unstructured":"Cladis, D. P., Kleiner, A. C., Freiser, H. H. & Santerre, C. R. Fatty acid profiles of commercially available finfish fillets in the United States. Lipids 49, 1005\u20131018 (2014).","journal-title":"Lipids"},{"key":"108_CR158","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jada.2008.04.023","volume":"108","author":"KL Weaver","year":"2008","unstructured":"Weaver, K. L. et al. The content of favorable and unfavorable polyunsaturated fatty acids found in commonly eaten fish. J. Am. Diet. Assoc. 108, 1178\u20131185 (2008).","journal-title":"J. Am. Diet Assoc."},{"key":"108_CR159","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/15287399409531853","volume":"41","author":"BG Svensson","year":"1994","unstructured":"Svensson, B. G., Akesson, B., Nilsson, A. & Paulsson, K. Urinary excretion of methylamines in men with varying intake of fish from the Baltic Sea. J. Toxicol. Environ. Health 41, 411\u2013420 (1994).","journal-title":"J. Toxicol. Environ. Health"},{"key":"108_CR160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/mnfr.201500537","volume":"60","author":"N Yazdekhasti","year":"2016","unstructured":"Yazdekhasti, N. et al. Fish protein increases circulating levels of trimethylamine-N-oxide and accelerates aortic lesion formation in apoE null mice. Mol. Nutr. Food Res. 60, 358\u2013368 (2016).","journal-title":"Mol. Nutr. Food Res."},{"key":"108_CR161","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1039\/C5FO00007F","volume":"6","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Fish oil ameliorates trimethylamine N-oxide-exacerbated glucose intolerance in high-fat diet-fed mice. Food Funct. 6, 1117\u20131125 (2015).","journal-title":"Food Funct"},{"key":"108_CR162","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1053\/ajkd.1998.v31.pm9631839","volume":"31","author":"BL Kasiske","year":"1998","unstructured":"Kasiske, B. L., Lakatua, J. D., Ma, J. Z. & Louis, T. A. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am. J. Kidney Dis. 31, 954\u2013961 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"108_CR163","doi-asserted-by":"crossref","first-page":"627","DOI":"10.7326\/0003-4819-124-7-199604010-00002","volume":"124","author":"MT Pedrini","year":"1996","unstructured":"Pedrini, M. T., Levey, A. S., Lau, J., Chalmers, T. C. & Wang, P. H. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann. Intern. Med. 124, 627\u2013632 (1996).","journal-title":"Ann. Intern. Med."},{"key":"108_CR164","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2015.10.108","volume":"244","author":"HL Collins","year":"2016","unstructured":"Collins, H. L. et al. L-carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE \u2212\/\u2212 transgenic mice expressing CETP. Atherosclerosis 244, 29\u201337 (2016).","journal-title":"Atherosclerosis"},{"key":"108_CR165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmet.2012.12.011","volume":"17","author":"BJ Bennett","year":"2013","unstructured":"Bennett, B. J. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17, 49\u201360 (2013).","journal-title":"Cell Metab."},{"key":"108_CR166","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.116.025338","volume":"135","author":"W Zhu","year":"2017","unstructured":"Zhu, W., Wang, Z., Tang, W. H. W. & Hazen, S. L. Gut microbe-generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects. Circulation 135, 1671\u20131673 (2017).","journal-title":"Circulation"},{"key":"108_CR167","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002767","volume":"5","author":"MM Seldin","year":"2016","unstructured":"Seldin, M. M. et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-kappaB. J. Am. Heart Assoc. 5, e002767 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"108_CR168","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbrc.2016.11.017","volume":"481","author":"X Sun","year":"2016","unstructured":"Sun, X. et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem. Biophys. Res. Commun. 481, 63\u201370 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"108_CR169","doi-asserted-by":"crossref","first-page":"BSR20160244","DOI":"10.1042\/BSR20160244","volume":"37","author":"G Ma","year":"2017","unstructured":"Ma, G. et al. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci. Rep. 37, BSR20160244 (2017).","journal-title":"Biosci. Rep."},{"key":"108_CR170","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1073\/pnas.0308633101","volume":"101","author":"BJ Bennion","year":"2004","unstructured":"Bennion, B. J. & Daggett, V. Counteraction of urea-induced protein denaturation by trimethylamine N-oxide: a chemical chaperone at atomic resolution. Proc. Natl Acad. Sci. USA 101, 6433\u20136438 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR171","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nature05066","volume":"442","author":"SD Liberles","year":"2006","unstructured":"Liberles, S. D. & Buck, L. B. A second class of chemosensory receptors in the olfactory epithelium. Nature 442, 645\u2013650 (2006).","journal-title":"Nature"},{"key":"108_CR172","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cjca.2014.09.010","volume":"30","author":"M Ufnal","year":"2014","unstructured":"Ufnal, M. et al. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can. J. Cardiol. 30, 1700\u20131705 (2014).","journal-title":"Can. J. Cardiol."},{"key":"108_CR173","first-page":"19293","volume":"134","author":"CL Organ","year":"2016","unstructured":"Organ, C. L. et al. Removal of dietary trimethylamine N-oxide (TMAO) attenuates cardiac dysfunction in pressure overload induced heart failure [abstract]. Circulation 134 (Suppl. 1), 19293 (2016).","journal-title":"Circulation"},{"key":"108_CR174","first-page":"139","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen, K., Zheng, X., Feng, M., Li, D. & Zhang, H. Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice. Front. Physiol. 8, 139 (2017).","journal-title":"Front. Physiol"},{"key":"108_CR175","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","volume":"64","author":"WH Tang","year":"2014","unstructured":"Tang, W. H. et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J. Am. Coll. Cardiol. 64, 1908\u20131914 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR176","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cardfail.2014.11.006","volume":"21","author":"WH Tang","year":"2015","unstructured":"Tang, W. H. et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J. Card. Fail. 21, 91\u201396 (2015).","journal-title":"J. Card Fail"},{"key":"108_CR177","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.12328","volume":"277","author":"M Troseid","year":"2015","unstructured":"Troseid, M. et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J. Intern. Med. 277, 717\u2013726 (2015).","journal-title":"J. Intern. Med."},{"key":"108_CR178","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1016\/j.jacc.2017.10.064","volume":"70","author":"K Schuett","year":"2017","unstructured":"Schuett, K. et al. Trimethylamine-N-oxide and heart failure with reduced versus preserved ejection fraction. J. Am. Coll. Cardiol. 70, 3202\u20133204 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"108_CR179","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/heartjnl-2015-308826","volume":"102","author":"T Suzuki","year":"2016","unstructured":"Suzuki, T., Heaney, L. M., Bhandari, S. S., Jones, D. J. & Ng, L. L. Trimethylamine N-oxide and prognosis in acute heart failure. Heart 102, 841\u2013848 (2016).","journal-title":"Heart"},{"key":"108_CR180","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23030549","volume":"23","author":"M Savi","year":"2018","unstructured":"Savi, M. et al. Trimethylamine-N-oxide (TMAO)-induced impairment of cardiomyocyte function and the protective role of urolithin B-glucuronide. Molecules 23, E549 (2018).","journal-title":"Molecules"},{"key":"108_CR181","first-page":"688.3","volume":"31","author":"C Oakley","year":"2017","unstructured":"Oakley, C. et al. The uremic metabolite, trimethylamine-N-oxide (TMAO), directly alters cardiac contractile function [abstract]. FASEB J. 31 (Suppl. 1), 688.3 (2017).","journal-title":"FASEB J."},{"key":"108_CR182","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","volume":"12","author":"JC Schefold","year":"2016","unstructured":"Schefold, J. C., Filippatos, G., Hasenfuss, G., Anker, S. D. & von Haehling, S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat. Rev. Nephrol. 12, 610\u2013623 (2016).","journal-title":"Nat. Rev. Nephrol"},{"key":"108_CR183","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","volume":"113","author":"HL Hillege","year":"2006","unstructured":"Hillege, H. L. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113, 671\u2013678 (2006).","journal-title":"Circulation"},{"key":"108_CR184","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","volume":"16","author":"VM Deursen van","year":"2014","unstructured":"van Deursen, V. M. et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur. J. Heart Fail. 16, 103\u2013111 (2014).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR185","doi-asserted-by":"crossref","first-page":"1600324","DOI":"10.1002\/mnfr.201600324","volume":"61","author":"CE Cho","year":"2017","unstructured":"Cho, C. E. et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol. Nutr. Food Res. 61, 1600324 (2017).","journal-title":"Mol. Nutr. Food Res."},{"key":"108_CR186","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/taap.1994.1076","volume":"125","author":"JL Smith","year":"1994","unstructured":"Smith, J. L., Wishnok, J. S. & Deen, W. M. Metabolism and excretion of methylamines in rats. Toxicol. Appl. Pharmacol. 125, 296\u2013308 (1994).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"108_CR187","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1085\/jgp.42.2.319","volume":"42","author":"RP Forster","year":"1958","unstructured":"Forster, R. P., Berglund, F. & Rennick, B. R. Tubular secretion of creatine, trimethylamine oxide, and other organic bases by the aglomerular kidney of Lophius americanus. J. Gen. Physiol. 42, 319\u2013327 (1958).","journal-title":"J. Gen. Physiol."},{"key":"108_CR188","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1152\/ajplegacy.1958.196.1.93","volume":"196","author":"JJ Cohen","year":"1959","unstructured":"Cohen, J. J., Krupp, M. A., Chidsey, C. A. 3rd & Biltz, C. I. Effect of trimethylamine and its homologues on renal conservation of trimethylamine oxide by the spiny dogfish, Squalus acanthias. Am. J. Physiol. 196, 93\u201399 (1959).","journal-title":"Am. J. Physiol."},{"key":"108_CR189","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0090-9556(25)05909-4","volume":"5","author":"M Acara","year":"1977","unstructured":"Acara, M., Camiolo, S. & Rennick, B. Renal N-oxidation of trimethylamine in the chicken during tubular excretion. Drug Metab. Dispos. 5, 82\u201390 (1977).","journal-title":"Drug Metab. Dispos."},{"key":"108_CR190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0925-4439(91)90046-C","volume":"1096","author":"JD Bell","year":"1991","unstructured":"Bell, J. D. et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim. Biophys. Acta 1096, 101\u2013107 (1991).","journal-title":"Biochim. Biophys. Acta"},{"key":"108_CR191","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1681\/ASN.2012101006","volume":"24","author":"EP Rhee","year":"2013","unstructured":"Rhee, E. P. et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J. Am. Soc. Nephrol. 24, 1330\u20131338 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"108_CR192","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","volume":"116","author":"WH Tang","year":"2015","unstructured":"Tang, W. H. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448\u2013455 (2015).","journal-title":"Circ. Res."},{"key":"108_CR193","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1681\/ASN.2014111063","volume":"27","author":"JR Stubbs","year":"2016","unstructured":"Stubbs, J. R. et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J. Am. Soc. Nephrol. 27, 305\u2013313 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"108_CR194","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.kint.2016.01.014","volume":"89","author":"RB Kim","year":"2016","unstructured":"Kim, R. B. et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int. 89, 1144\u20131152 (2016).","journal-title":"Kidney Int."},{"key":"108_CR195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1681\/ASN.2016030374","volume":"28","author":"T Shafi","year":"2017","unstructured":"Shafi, T. et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients. J. Am. Soc. Nephrol. 28, 321\u2013331 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"108_CR196","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141738","volume":"11","author":"C Missailidis","year":"2016","unstructured":"Missailidis, C. et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLOS ONE 11, e0141738 (2016).","journal-title":"PLOS ONE"},{"key":"108_CR197","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13739-9","volume":"7","author":"EG Gruppen","year":"2017","unstructured":"Gruppen, E. G. et al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci. Rep. 7, 13781 (2017).","journal-title":"Sci. Rep."},{"key":"108_CR198","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/ATVBAHA.114.303252","volume":"34","author":"J Hartiala","year":"2014","unstructured":"Hartiala, J. et al. Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler. Thromb. Vasc. Biol. 34, 1307\u20131313 (2014).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"108_CR199","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161074","volume":"11","author":"C Robinson-Cohen","year":"2016","unstructured":"Robinson-Cohen, C. et al. Association of FMO3 variants and trimethylamine N-oxide concentration, disease progression, and mortality in CKD patients. PLOS ONE 11, e0161074 (2016).","journal-title":"PLOS ONE"},{"key":"108_CR200","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1124\/dmd.118.081646","volume":"46","author":"C Johnson","year":"2018","unstructured":"Johnson, C., Prokopienko, A. J., West, R. E. 3rd, Nolin, T. D. & Stubbs, J. R. Decreased kidney function is associated with enhanced hepatic flavin monooxygenase activity and increased circulating trimethylamine N-oxide concentrations in mice. Drug Metab. Dispos. 46, 1304\u20131309 (2018).","journal-title":"Drug Metab. Dispos."},{"key":"108_CR201","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004947","volume":"6","author":"Y Heianza","year":"2017","unstructured":"Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J. Am. Heart Assoc. 6, e004947 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"108_CR202","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jcmm.13307","volume":"22","author":"J Qi","year":"2017","unstructured":"Qi, J. et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J. Cell. Mol. Med. 22, 185\u2013194 (2017).","journal-title":"J. Cell. Mol. Med."},{"key":"108_CR203","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","volume":"38","author":"GG Schiattarella","year":"2017","unstructured":"Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur. Heart J. 38, 2948\u20132956 (2017).","journal-title":"Eur. Heart J."},{"key":"108_CR204","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/CIRCHEARTFAILURE.113.000978","volume":"7","author":"XT Gan","year":"2014","unstructured":"Gan, X. T. et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ. Heart Fail. 7, 491\u2013499 (2014).","journal-title":"Circ. Heart Fail"},{"key":"108_CR205","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijcard.2014.11.034","volume":"179","author":"AC Costanza","year":"2015","unstructured":"Costanza, A. C., Moscavitch, S. D., Faria Neto, H. C. & Mesquita, E. T. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int. J. Cardiol. 179, 348\u2013350 (2015).","journal-title":"Int. J. Cardiol."},{"key":"108_CR206","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1469-0691.2011.03614.x","volume":"17","author":"P Kochan","year":"2011","unstructured":"Kochan, P. et al. Lactobacillus rhamnosus administration causes sepsis in a cardiosurgical patient\u2014is the time right to revise probiotic safety guidelines? Clin. Microbiol. Infect. 17, 1589\u20131592 (2011).","journal-title":"Clin. Microbiol. Infect."},{"key":"108_CR207","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1753-4887.2008.00024.x","volume":"66","author":"MT Liong","year":"2008","unstructured":"Liong, M. T. Safety of probiotics: translocation and infection. Nutr. Rev. 66, 192\u2013202 (2008).","journal-title":"Nutr. Rev."},{"key":"108_CR208","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.nut.2012.12.018","volume":"29","author":"A Salehi-Abargouei","year":"2013","unstructured":"Salehi-Abargouei, A., Maghsoudi, Z., Shirani, F. & Azadbakht, L. Effects of dietary approaches to stop hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases\u2014incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition 29, 611\u2013618 (2013).","journal-title":"Nutrition"},{"key":"108_CR209","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archinternmed.2009.56","volume":"169","author":"EB Levitan","year":"2009","unstructured":"Levitan, E. B., Wolk, A. & Mittleman, M. A. Consistency with the DASH diet and incidence of heart failure. Arch. Intern. Med. 169, 851\u2013857 (2009).","journal-title":"Arch. Intern. Med."},{"key":"108_CR210","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjcard.2009.06.061","volume":"104","author":"EB Levitan","year":"2009","unstructured":"Levitan, E. B., Wolk, A. & Mittleman, M. A. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am. J. Cardiol. 104, 1416\u20131420 (2009).","journal-title":"Am. J. Cardiol."},{"key":"108_CR211","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/07315724.2012.10720466","volume":"31","author":"HT Nguyen","year":"2012","unstructured":"Nguyen, H. T. et al. DASH eating pattern is associated with favorable left ventricular function in the multi-ethnic study of atherosclerosis. J. Am. Coll. Nutr. 31, 401\u2013407 (2012).","journal-title":"J. Am. Coll. Nutr."},{"key":"108_CR212","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/08998280.2015.11929216","volume":"28","author":"L Rifai","year":"2015","unstructured":"Rifai, L., Pisano, C., Hayden, J., Sulo, S. & Silver, M. A. Impact of the DASH diet on endothelial function, exercise capacity, and quality of life in patients with heart failure. Proc. (Bayl Univ. Med. Cent.) 28, 151\u2013156 (2015).","journal-title":"Proc. (Bayl Univ. Med. Cent.)"},{"key":"108_CR213","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cardfail.2015.10.003","volume":"21","author":"AV Mathew","year":"2015","unstructured":"Mathew, A. V., Seymour, E. M., Byun, J., Pennathur, S. & Hummel, S. L. Altered metabolic profile with sodium-restricted dietary approaches to stop hypertension diet in hypertensive heart failure with preserved ejection fraction. J. Card. Fail. 21, 963\u2013967 (2015).","journal-title":"J. Card Fail"},{"key":"108_CR214","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","volume":"6","author":"SL Hummel","year":"2013","unstructured":"Hummel, S. L. et al. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ. Heart Fail. 6, 1165\u20131171 (2013).","journal-title":"Circ. Heart Fail"},{"key":"108_CR215","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/HYPERTENSIONAHA.112.202705","volume":"60","author":"SL Hummel","year":"2012","unstructured":"Hummel, S. L. et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 60, 1200\u20131206 (2012).","journal-title":"Hypertension"},{"key":"108_CR216","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc1806491","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch, R. et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N. Engl. J. Med. 378, e34 (2018).","journal-title":"N. Engl. J. Med."},{"key":"108_CR217","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ejhf.750","volume":"19","author":"A Papadaki","year":"2017","unstructured":"Papadaki, A. et al. Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial. Eur. J. Heart Fail. 19, 1179\u20131185 (2017).","journal-title":"Eur. J. Heart Fail"},{"key":"108_CR218","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jchf.2017.09.020","volume":"6","author":"O Miro","year":"2018","unstructured":"Miro, O. et al. Adherence to mediterranean diet and all-cause mortality after an episode of acute heart failure: results of the MEDIT-AHF study. JACC Heart Fail. 6, 52\u201362 (2018).","journal-title":"JACC Heart Fail"},{"key":"108_CR219","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev-micro-091014-104422","volume":"69","author":"G Falony","year":"2015","unstructured":"Falony, G., Vieira-Silva, S. & Raes, J. Microbiology meets big data: the case of gut microbiota-derived trimethylamine. Annu. Rev. Microbiol. 69, 305\u2013321 (2015).","journal-title":"Annu. Rev. Microbiol."},{"key":"108_CR220","doi-asserted-by":"crossref","first-page":"21307","DOI":"10.1073\/pnas.1215689109","volume":"109","author":"S Craciun","year":"2012","unstructured":"Craciun, S. & Balskus, E. P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl Acad. Sci. USA 109, 21307\u201321312 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR221","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmet.2014.10.006","volume":"20","author":"RA Koeth","year":"2014","unstructured":"Koeth, R. A. et al. \u03b3-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 20, 799\u2013812 (2014).","journal-title":"Cell Metab."},{"key":"108_CR222","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1432-1033.1995.184_c.x","volume":"234","author":"M Meyer","year":"1995","unstructured":"Meyer, M., Granderath, K. & Andreesen, J. R. Purification and characterization of protein PB of betaine reductase and its relationship to the corresponding proteins glycine reductase and sarcosine reductase from Eubacterium acidaminophilum. Eur. J. Biochem. 234, 184\u2013191 (1995).","journal-title":"Eur. J. Biochem."},{"key":"108_CR223","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1432-1327.1999.00107.x","volume":"260","author":"M Wagner","year":"1999","unstructured":"Wagner, M. et al. Substrate-specific selenoprotein B of glycine reductase from Eubacterium acidaminophilum. Biochemical and molecular analysis. Eur. J. Biochem. 260, 38\u201349 (1999).","journal-title":"Eur. J. Biochem."},{"key":"108_CR224","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1073\/pnas.1316569111","volume":"111","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y. et al. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl Acad. Sci. USA 111, 4268\u20134273 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"108_CR225","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lfs.2014.09.028","volume":"117","author":"J Kuka","year":"2014","unstructured":"Kuka, J. et al. Suppression of intestinal microbiota-dependent production of pro-atherogenic trimethylamine N-oxide by shifting L-carnitine microbial degradation. Life Sci. 117, 84\u201392 (2014).","journal-title":"Life Sci."},{"key":"108_CR226","volume":"7","author":"ML Chen","year":"2016","unstructured":"Chen, M. L. et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio 7, e02210 (2016).","journal-title":"MBio"},{"key":"108_CR227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00109-016-1492-2","volume":"95","author":"EL Johnson","year":"2017","unstructured":"Johnson, E. L., Heaver, S. L., Walters, W. A. & Ley, R. E. Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes. J. Mol. Med. 95, 1\u20138 (2017).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"108_CR228","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nature09944","volume":"473","author":"M Arumugam","year":"2011","unstructured":"Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174\u2013180 (2011).","journal-title":"Nature"},{"key":"108_CR229","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrmicro2859","volume":"10","author":"IB Jeffery","year":"2012","unstructured":"Jeffery, I. B., Claesson, M. J., O\u2019Toole, P. W. & Shanahan, F. Categorization of the gut microbiota: enterotypes or gradients? Nat. Rev. Microbiol. 10, 591\u2013592 (2012).","journal-title":"Nat. Rev. Microbiol."},{"key":"108_CR230","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chom.2014.09.013","volume":"16","author":"D Knights","year":"2014","unstructured":"Knights, D. et al. Rethinking \u201centerotypes\u201d. Cell Host Microbe 16, 433\u2013437 (2014).","journal-title":"Cell Host Microbe"},{"key":"108_CR231","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nbt.2942","volume":"32","author":"J Li","year":"2014","unstructured":"Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834\u2013841 (2014).","journal-title":"Nat. Biotechnol."},{"key":"108_CR232","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00042-15","volume":"6","author":"A Martinez-del Campo","year":"2015","unstructured":"Martinez-del Campo, A. et al. Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. MBio 6, e00042 (2015).","journal-title":"MBio"},{"key":"108_CR233","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4093\/dmj.2015.39.3.198","volume":"39","author":"KY Hur","year":"2015","unstructured":"Hur, K. Y. & Lee, M. S. Gut microbiota and metabolic disorders. Diabetes Metab. J. 39, 198\u2013203 (2015).","journal-title":"Diabetes Metab. J."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41569-018-0108-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-018-0108-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-018-0108-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:25:10Z","timestamp":1775262310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-018-0108-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":233,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1038\/s41569-018-0108-7","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"8 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.H. is named as a co-inventor on pending and issued patents held by the Cleveland Clinic, USA, relating to cardiovascular diagnostics and therapeutics; he is a paid consultant for Proctor & Gamble and has received research funds from Proctor & Gamble and Roche Diagnostics; and he is eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab\/Quest Diagnostics or Proctor & Gamble. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}